DUBLIN, December 17, 2025 — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today shared details of its participation in the following upcoming investor events:

Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026

• Jazz will host an investor webcast on Friday, January 9, 2026, at 6:30 a.m. PT / 3:30 p.m. GMT to discuss results from the Phase 3 zanidatamab HERIZON-GEA-01 trial. The webcast will feature comments from the company’s senior management team and Dr. Geoffrey Ku, Associate Attending Physician in the Gastrointestinal Oncology Service within the Department of Medicine at Memorial Sloan Kettering Cancer Center. The session will follow an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026.

44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026

• Jazz will stream its corporate presentation at the 44^th Annual J.P. Morgan Healthcare Conference. Renee Gala, President and Chief Executive Officer, will deliver an overview of the company’s strategy and a business update on Tuesday, January 13, 2026, at 11:15 a.m. PST / 7:15 p.m. GMT.

Audio webcasts of the presentations can be accessed through the Investors section of the Jazz Pharmaceuticals website at . Replays of the webcasts will be available on the website for 30 days.  

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose mission is to innovate to transform the lives of patients and their families. We are focused on developing potentially life-changing medicines for people with serious diseases—often those with limited or no treatment options. Our marketed portfolio includes leading therapies for sleep disorders and epilepsy, as well as a growing range of cancer treatments. Our patient-first, science-driven approach fuels pioneering research and development advances across our robust pipeline of innovative oncology and neuroscience therapeutics. Headquartered in Dublin, Ireland, Jazz has research and development labs, manufacturing facilities and employees in multiple countries, all committed to serving patients worldwide. For more information, visit .

Contacts:

Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc

Ireland: +353 1 634 3211
U.S.: +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Ireland: +353 1 637 2141
U.S.: +1 215 867 4948

 

SOURCE Jazz Pharmaceuticals plc